Mass­a­chu­setts biotech Re­vi­tope scores first col­lab­o­ra­tion thanks to dual-en­gag­ing T cell plat­form

Re­vi­tope On­col­o­gy be­gan 2020 hope­ful that its can­cer im­munol­o­gy plat­form would be fi­nal­ly ready to flour­ish. On Mon­day night, that plat­form nabbed the biotech its first col­lab­o­ra­tion.

The Mass­a­chu­setts-based com­pa­ny has agreed to a li­cens­ing agree­ment with Shang­hai-based Jun­shi Bio­sciences in which Re­vi­tope can re­ceive up to $160 mil­lion in de­vel­op­ment and com­mer­cial mile­stones, plus roy­al­ties. In ad­di­tion, Jun­shi will make a di­rect eq­ui­ty in­vest­ment of $10 mil­lion, equal to 9.99% of Re­vi­tope shares, as the two com­pa­nies work to de­vel­op a dual-anti­gen tar­get­ing can­cer ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER